AALL1521 - A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK PathwayMutant Acute Lymphoblastic Leukemia
A study for children, adolescents and young adults with high-risk acute lymphoblastic Leukemia (HR B-ALL) using study drug Ruxolitinib
Sponsor: Incyte Corporation
Enrolling: Male and Female Patients
IRB Number: AAAQ8903
U.S. Govt. ID: NCT02723994
Contact: Alice Lee: 212-305-5808 / al2041@cumc.columbia.edu
Additional Study Information: This study is for children who have been diagnosed with High Risk (HR) B-ALL, a type of cancer of the blood cells that occurs in the bone marrow. This research study will find out if the study drug, ruxolitinib (a tyrosine kinase inhibitor), in combination with standard HR B-ALL treatment is safe and effective in children, adolescents, and young adults with HR B-ALL.
This study is closed
Investigator
Alice Lee, MD
Do You Qualify?
Have you or your child been diagnosed with HR B-ALL? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Alice Lee
al2041@cumc.columbia.edu
212-305-5808
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE